{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-056020","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.820578+00:00","generated_at":"2026-05-16T02:10:21.654852+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NewAmsterdam Pharma reports $728.9M cash, obicetrapib regulatory decisions expected 2H26","bullets":["Regulatory decisions from EMA, UK, Switzerland for obicetrapib monotherapy & FDC expected in 2H26.","Cash position $728.9M at Dec 31, 2025; net loss $203.8M for FY2025.","Topline data from RUBENS Phase 3 trial (type 2 diabetes/metabolic syndrome) expected by year-end 2026.","PREVAIL CVOT blinded event rate through initial 12 months tracking in line with BROADWAY.","Plan to initiate Alzheimer's disease trial in 2026 based on positive biomarker data from BROADWAY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-056020","json":"https://secwatch.observer/filing/0001193125-26-056020.json","markdown":"https://secwatch.observer/filing/0001193125-26-056020.md","text":"https://secwatch.observer/filing/0001193125-26-056020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/0001193125-26-056020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/nams-20260218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:10:21.654852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}